Actavis Acquires Chinese Manufacturer

Ramesh, Deepti
April 2008
Chemical Week;4/14/2008, Vol. 170 Issue 12, p33
Trade Publication
The article focuses on the confirmation made by Generics pharmaceutical manufacturer Actavis of Hafnarfjordur, Iceland that it has acquired 90 percent of active pharmaceutical ingredient (API) producer Zhejiang Chiral Medicine Chemicals Co. of Hangzhou, China. Terms of the deal were not disclosed. Actavis says the acquisition is part of its strategy to obtain direct access to low-cost API manufacturing.


Related Articles

  • Established Presence.  // Retail Merchandiser;Nov/Dec2009, Vol. 49 Issue 6, p128 

    The article explores how Actavis Group, a generic pharmaceutical manufacturer successfully entered the U.S. market and established Actavis Inc. The company is ranked fifth in terms of size among the world's generic pharmaceutical manufacturers. It relates how Actavis' acquisitions of Amide...

  • Actavis eyes more strategic acquisitions. Mirasol, Feliza; Chang, Joseph // ICIS Chemical Business Americas;10/2/2006, Vol. 270 Issue 12, p7 

    The article reports that Actavis despite having withdrawn its $2.5 billion bid for Pliva, a Croatian generic drug firm, Actavis still hopes to aquire the company if rival Barr Pharmaceuticals fails. The article reports that according to Actavis President and Cheif Executive, Robert Wessman, the...

  • Full steam ahead for Actavis in generics.  // Chemical Market Reporter;7/17/2006, Vol. 270 Issue 2, p24 

    The article announces that Iceland-based Actavis is pushing through with its generic pharmaceuticals business in its attempt to attain a leading position in the worldwide generic drug industry. Actavis now sells dantrolene and isradipine in the United States. It also markets amantadine,...

  • Watson pays $5.6B for Swiss drugmaker. Eder, Katie // njbiz;4/30/2012, Vol. 25 Issue 18, p12 

    The article reports that Parsippany, New Jersey-based Watson Pharmaceuticals Inc. has agreed to acquire Switzerland-based drug manufacturer Actavis Group for 5.6-billion dollars, creating the third-largest global generics firm in the world with an anticipated 2012 revenue of 8-billion dollars.

  • Actavis eyes more strategic acquisitions. Mirasol, Feliza; Chang, Joseph // ICIS Chemical Business Americas;10/2/2006, Vol. 270 Issue 12, p7 

    The article reports the intention of Iceland based-Actavis company of acquiring Pliva, a Croatian generic drug conglomerate, if rival Barr Pharmaceuticals fails in its bid. The article outlines the requirement of acquisition and achieving critical mass by generic drug companies to survive in the...

  • MERGERS AND ACQUISITIONS.  // European Pharmaceutical Executive;Feb/Mar2007, p13 

    The article presents news briefs concerning mergers and acquisitions in the pharmaceutical industry. WPP's wholly-owned operating company Grey Healthcare Group has acquired a majority stake in Communicacion y Servicio Consultores de Marketing Publicidad SL. Galapagos NV plans to acquire...

  • Barr continues bidding war for Croatia's Pliva. Mirasol, Feliza // ICIS Chemical Business Americas;9/11/2006, Vol. 270 Issue 9, p32 

    The article reports on the competition between Barr Pharmaceuticals and Actavis in a bid to acquire Pliva. The value of the acquisition offer from Bar and Actavis is discussed. The sources of Barr's funding for the acquisition are disclosed. The key advantage of the merger of Barr and Pliva is...

  • Actavis to Build Three Plants in India; Opens Laboratories. Ramesh, Deepti // Chemical Week;11/3/2008, Vol. 170 Issue 34, p31 

    The article reports on the announcement by generics pharmaceutical manufacturer Actavis that it is building three pharmaceutical plants in India. It broke ground on a pilot plant and an active pharmaceutical ingredient (API) plant at the company's existing API facility at Alathur, in southern...

  • Actavis Expands into New Markets; May Enter Biosimilars. Ramesh, Deepti // Chemical Week;10/26/2009, Vol. 171 Issue 26, p31 

    The article reports on the decision of generic pharmaceuticals producer Actavis to expand its operations in other regions. According to Stefan Sveinsson, executive vice president of Actavis, the company is planning to enter the biosimilars market through joint ventures and partnerships....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics